secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K/A
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001104659-25-096071
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives
--------------------------------------------------------------------------------

- Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).
- Expects ~$0.4M in restructuring costs (severance/benefits), substantially in Q4 2025.
- Entered retention agreements: CEO Todd Bazemore ($183,750), CFO Mary Reumuth ($136,250), CMO Kim Brazzell ($145,000).
- Company preserving cash while exploring strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000110465925096071/0001104659-25-096071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000110465925096071/tm2527808d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-096071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer